Volume 69, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


The sporontocidal activity of tafenoquine (WR-238605) and artelinic acid was determined against naturally circulating isolates of in western Thailand. Primaquine was used as a negative control and a dihydroacridine-dione (WR-250547) was used as a positive control. Laboratory-reared mosquitoes were infected with by allowing mosquitoes to feed on blood (placed in an artificial-membrane feeding apparatus) collected from gametocytemic volunteers reporting to local malaria clinics in Tak province, Thailand. Four days post-infection, mosquitoes were refed on uninfected mice treated 90 minutes earlier with a given drug. Drug activity was determined by assessing oocyst and sporozoite development. Neither primaquine nor artelinic acid affected oocyst or sporozoite development at a dose of 100 mg of base drug/kg of mouse body weight. In contrast, tafenoquine and WR-250547 affected sporogonic development at doses as low as 25.0 and 0.39 mg/kg, respectively. The potential role of these compounds in the prevention of malaria transmission is discussed, as are alternative strategies for the use of transmission-blocking antimalarial drugs.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. World Health Organization, 1987. The Biology of Malaria Parasites. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 743. Geneva.
  2. Gilles HM, Warrell DA, 1993. Bruce-Chwatt’s Essential Malariology. Third edition. London: Edward Arnold, 164–195.
  3. Oaks SC, Mitchell VS, Pearson GW, Carpenter CCJ, 1991. Malaria: Obstacles and Opportunities. Washington: National Academy Press.
  4. Coleman RE, Ponsa N, Eikarat N, Kollars TM Jr, Sattabongkot J, 2001. Prevention of sporogony of Plasmodium vivax in Anopheles dirus mosquitoes by transmission-blocking antimalarials. Am J Trop Med Hyg 65 : 214–218. [Google Scholar]
  5. Coleman RE, Nath AK, Schneider I, Song G-H, Klein TA, Milhous WK, 1994. Transmission-blocking antimalarials prevent sporogony of Plasmodium falciparum and P. berghei in Anopheles stephensi mosquitoes. Am J Trop Med Hyg 50 : 646–653. [Google Scholar]
  6. Coleman RE, Clavin AM, Milhous WK, 1992. Gametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR mice and Anopheles stephensi mosquitoes. Am J Trop Med Hyg 46 : 169–182. [Google Scholar]
  7. Coleman RE, 1990. Sporontocidal activity of the antimalarial WR-238605 against Plasmodium berghei ANKA in Anopheles stephensi. Am J Trop Med Hyg 42 : 196–205. [Google Scholar]
  8. Butcher GA, 1997. Antimalarial drugs and the mosquito transmission of Plasmodium. Int J Parasitol 27 : 975–987. [Google Scholar]
  9. Teklehaimanot A, Nguyen-Dinh P, Collins WE, Barber AM, Campbell CC, 1985. Evaluation of sporontocidal compounds using Plasmodium falciparum gametocytes produced in vitro. Am J Trop Med Hyg 34 : 429–434. [Google Scholar]
  10. Coleman RE, Maneechai N, Yim-Amnuaychok N, Kumpitak C, Soyseng V, Miller RS, Thimasarn K, Sattabongkot J, 2002. Field evaluation of the ICT malaria Pf/Pv immunochromatographic test for the detection of asymptomatic malaria in a Plasmodium falciparum/vivax endemic area in Thailand. Am J Trop Med Hyg 66 : 379–383. [Google Scholar]
  11. Young MD, 1959. The effect of small doses of primaquine upon malaria infections. Indian J Malariol 13 : 69–74. [Google Scholar]
  12. Brueckner RP, Lasseter KC, Lin ET, Schuster BG, 1998. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg 58 : 645–649. [Google Scholar]
  13. Milhous WK, 2001. Development of new drugs for chemoprophylaxis of malaria. Med Trop (Mars) 61 : 48–50. [Google Scholar]
  14. Peters W, 1999. The evolution of tafenoquine—antimalarial for a new millennium? J R Soc Med 92 : 345–352. [Google Scholar]
  15. Brueckner RP, Coster T, Wesche DL, Shmuklarsky M, Schuster BG, 1998. Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial. Antimicrob Agents Chemother 42 : 1293–1294. [Google Scholar]
  16. Lell B, Faucher JF, Missinou MA, Borrmann S, Dangelmaier O, Horton J, Kremsner PG, 2000. Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet 355 : 2041–2045. [Google Scholar]
  17. Edstein MD, Walsh DS, Eamsila C, Sasiprapha T, Nasveld PE, Kitchener S, Rieckmann KH, 2001. Malaria prophylaxis/ radical cure: recent experiences of the Australian Defence Force. Med Trop (Mars) 61 : 56–58. [Google Scholar]
  18. Cooper RD, Milhous WK, Rieckmann KH, 1994. The efficacy of WR 238605 against the blood stages of a chloroquine resistant strain of Plasmodium vivax. Trans R Soc Trop Med Hyg 88 : 691–692. [Google Scholar]
  19. Peters W, Robinson BL, Milhous WK, 1993. The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605. Ann Trop Med Parasitol 87 : 547–552. [Google Scholar]
  20. Obaldia N III, Rossan RN, Cooper RD, Kyle DE, Nuzum EO, Rieckmann KH, Shanks GD, 1997. WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys. Am J Trop Med Hyg 56 : 508–510. [Google Scholar]
  21. Tripathi R, Puri SK, Dutta GP, 1996. Sodium β-artelinate—A new potential gametocytocide. Exp Parasitol 82 : 251–254. [Google Scholar]
  22. Mehra N, Bhasin VK, 1993. In vitro gametocytocidal activity of artemesinin and its derivatives on Plasmodium falciparum. Jpn J Med Sci Biol 46 : 37–43. [Google Scholar]
  23. Chen PQ, Li GQ, Guo XB, He KR, Fu YX, Fu LC, Song YZ, 1994. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chin Med J 107 : 709–711. [Google Scholar]
  24. Price RN, 2000. Artemisinin drugs: novel antimalarial agents. Expert Opin Investig Drugs 9 : 1815–1827. [Google Scholar]
  25. Labbe AC, Loutfy MR, Kain KC, 2001. Recent advances in the prophylaxis and treatment of Malaria. Curr Infect Dis Rep 3 : 68–76. [Google Scholar]
  26. Lopez-Antunano FJ, 1999. Is primaquine useful and safe as true exo-erythrocytic merontocidal, hypnozoitocidal and gametocidal antimalarial drug? Salud Publica Mex 41 : 410–419. [Google Scholar]
  27. Thimasarn K, 1992. Current measures of containment of multi-drug resistant falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health 23 (Suppl 4): 139–142. [Google Scholar]
  28. Jong EC, Nothdurft HD, 2001. Current drugs for antimalarial chemoprophylaxis: a review of efficacy and safety. J Travel Med 8 (Suppl 3): S48–S56. [Google Scholar]
  29. Shanks GD, Kain KC, Keystone JS, 2001. Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future. Clin Infect Dis 33 : 381–385. [Google Scholar]
  30. Kain KC, Shanks GD, Keystone JS, 2001. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. Clin Infect Dis 33 : 226–234. [Google Scholar]
  31. Li QG, Peggins JO, Lin AJ, Masonic KJ, Trotman KM, Brewer TG, 1998. Pharmacology and toxicology of artelinic acid: pre-clinical investigations on pharmacokinetics, metabolism, protein and red blood cell binding, and acute and anorectic toxicities. Trans R Soc Trop Med Hyg 92 : 332–340. [Google Scholar]
  32. Institute of Medicine, 1991. Malaria: Obstacles and Opportunities. Oaks SC, Mitchell VS, Pearson GW, Carpenter CCJ, eds. Washington, DC: National Academy Press.

Data & Media loading...

  • Received : 31 Oct 2002
  • Accepted : 20 Jan 2003

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error